88 related articles for article (PubMed ID: 16574318)
21. Targeting biliverdin reductase overcomes multidrug resistance in leukemia HL60 cells.
Kim SS; Seong S; Lim SH; Kim SY
Anticancer Res; 2013 Nov; 33(11):4913-9. PubMed ID: 24222129
[TBL] [Abstract][Full Text] [Related]
22. Effect of mitoxantrone liposomes on multidrug-resistant breast cancer cells.
Poujol S; Tilleul P; Astre C; Martel P; Fabbro M; Pinguet F
Anticancer Res; 1999; 19(4B):3327-31. PubMed ID: 10652629
[TBL] [Abstract][Full Text] [Related]
23. Antitumour effects of selected plant polyphenols, gallic acid and ellagic acid, on sensitive and multidrug-resistant leukaemia HL60 cells.
Maruszewska A; Tarasiuk J
Phytother Res; 2019 Apr; 33(4):1208-1221. PubMed ID: 30838722
[TBL] [Abstract][Full Text] [Related]
24. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
Ji BS; He L
J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumour effects of HL-37, a novel anthracene derivative, in-vivo and in-vitro.
Xie SQ; Hu GQ; Zhang ZQ; Xu M; Ji BS
J Pharm Pharmacol; 2008 Feb; 60(2):213-9. PubMed ID: 18237469
[TBL] [Abstract][Full Text] [Related]
26. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
27. The role of structural factors in the kinetics of cellular uptake of pyrazoloacridines and pyrazolopyrimidoacridines: implications for overcoming multidrug resistance towards leukaemia K562/DOX cells.
Tarasiuk J; Majewska E; Seksek O; Rogacka D; Antonini I; Garnier-Suillerot A; Borowski E
Biochem Pharmacol; 2004 Nov; 68(9):1815-23. PubMed ID: 15450947
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxicity and cellular uptake of doxorubicin and its formamidine derivatives in HL60 sensitive and HL60/MX2 resistant cells.
Kik K; Wasowska-Lukawska M; Oszczapowicz I; Szmigiero L
Anticancer Res; 2009 Apr; 29(4):1429-33. PubMed ID: 19414398
[TBL] [Abstract][Full Text] [Related]
29. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines.
Reske SN; Deisenhofer S; Glatting G; Zlatopolskiy BD; Morgenroth A; Vogg AT; Buck AK; Friesen C
J Nucl Med; 2007 Jun; 48(6):1000-7. PubMed ID: 17504875
[TBL] [Abstract][Full Text] [Related]
30. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
31. Effects of celecoxib on the reversal of multidrug resistance in human gastric carcinoma by downregulation of the expression and activity of P-glycoprotein.
Huang L; Wang C; Zheng W; Liu R; Yang J; Tang C
Anticancer Drugs; 2007 Oct; 18(9):1075-80. PubMed ID: 17704658
[TBL] [Abstract][Full Text] [Related]
32. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
33. Evidence for human liver mediated free-radical formation by doxorubicin and mitozantrone.
Basra J; Wolf CR; Brown JR; Patterson LH
Anticancer Drug Des; 1985 Oct; 1(1):45-52. PubMed ID: 2835961
[TBL] [Abstract][Full Text] [Related]
34. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
35. Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH.
Deng S; Kruger A; Kleschyov AL; Kalinowski L; Daiber A; Wojnowski L
Free Radic Biol Med; 2007 Feb; 42(4):466-73. PubMed ID: 17275678
[TBL] [Abstract][Full Text] [Related]
36. Chloro acridone derivatives as cytotoxic agents active on multidrug-resistant cell lines and their duplex DNA complex studies by electrospray ionization mass spectrometry.
Rajendra Prasad VV; Venkat Rao J; Giri RS; Sathish NK; Shanta Kumar SM; Mayur YC
Chem Biol Interact; 2008 Nov; 176(2-3):212-9. PubMed ID: 18638463
[TBL] [Abstract][Full Text] [Related]
37. Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells.
Ma Y; Wink M
Phytomedicine; 2008 Sep; 15(9):754-8. PubMed ID: 18222670
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.
Hermanson DL; Das SG; Li Y; Xing C
Mol Pharmacol; 2013 Aug; 84(2):236-43. PubMed ID: 23696245
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance.
Baran Y; Gür B; Kaya P; Ural AU; Avcu F; Gündüz U
Hematology; 2007 Dec; 12(6):511-7. PubMed ID: 17852453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
